## CMB International Securities | Equity Research | Company Update



#### 招商银行全资附属机构 A Wholly Owned Subsidiary Of China Merchants Bank

# **BYD Electronics (285 HK)**

## FY20 in-line; Reiterate BUY with multiple drivers ahead

BYDE reported FY20 revenue/net profit growth of 38%/241% YoY. Earnings was in-line given stronger GPM, and revenue was 4%/7% below our/consensus estimate, due to weaker casing (Huawei) and mask demand in 4Q20. Looking into 2021, we remain positive on BYDE as the major beneficiary of industry consolidation and Apple/ Xiaomi's supplier diversification strategy. We slightly adjusted our EPS to reflect lower mask demand, e-cigarette sales and higher share gain from Xiaomi/iPad. Our new SOTP-based TP of HK\$56.2 implies 17.9x FY21E P/E. Reiterate Buy.

- Results inline despite weaker mask and casing in 4Q20. 4Q net profit jumped 94% YoY while revenue grew 48% YoY, slightly below our estimates, mainly due to short-term impact from Huawei ban and weaker mask sales on easing COVID-19. Looking ahead, mgmt. targets to achieve RMB100bn revenue in FY21E, thanks to 1) Android demand recovery, 2) share gain in metal/glass front cover, 3) Apple's iPad OEM share gain, and 4) Apple's watch/NB/pad component ramp. Mgmt. believes Xiaomi and Honor will become major drivers from Android clients in 2021.
- Apple: Share gain in iPad/Watch EMS/components. Mgmt. expects Apple will become BYDE's largest customer in FY21E (30% of sales). We believe BYDE will expand its iPad share allocation to 30-40% in 2021 (vs 20-30% for one model in FY20, and we estimate Apple revenue will jump 3 times in FY21E. As we believe Apple will continue to diversify component suppliers, we expect BYDE to gain share in iPhone/Watch ceramic products and also penetrate into iPad metal casing and front glass. We forecast Apple revenue will reach RMB50bn in FY23E.
- Our FY21/22E EPS are 18%/13% above consensus; Reiterate BUY. We remain positive on BYDE's product roadmap, share gain in major brands and expansion into medical segment. We revised our SOTP-based TP to HK\$56.2 to reflect weaker mask demand but higher sales from Apple and medical segment. Our TP implies an undemanding valuation of 17.9x FY21E P/E. Catalysts include faster share gain, stronger mask and Xiaomi/Apple product launches.

## **Earnings Summary**

(YE 31 Dec)	FY19A	FY20A	FY21E	FY22E	FY23E
Revenue (RMB mn)	53,028	73,121	102,033	122,932	151,077
YoY growth (%)	29.2	37.9	39.5	20.5	22.9
Net income (RMB mn)	1,598	5,441	5,878	6,404	7,448
EPS (RMB)	0.71	2.41	2.61	2.84	3.31
YoY growth (%)	(25.5)	240.6	8.0	9.0	16.3
Consensus EPS (RMB)	NA	2.45	2.21	2.51	3.30
P/E (x)	49.6	14.6	13.5	12.4	10.6
P/B (x)	6.8	5.3	4.2	3.5	2.9
Yield (%)	0.2	0.7	0.7	0.8	0.9
ROE (%)	9.4	24.9	21.6	19.4	18.8
Net gearing (%)	Net cash				
0 0					

Source: Company data, Bloomberg, CMBIS estimates

## **BUY (Maintain)**

Target Price HK\$56.2
(Previous TP HK\$49.5)
Up/Downside +33%
Current Price HK\$42.40

### **China Technology Sector**

### Alex Ng

(852) 3900 0881 alexng@cmbi.com.hk

### Stock Data

Mkt. Cap. (HK\$mn)	95,423
Avg. 3mths t/o (HK\$mn)	642.28
52W High/Low (HK\$)	63.10/ 12.12
Total Issued Shares (mn)	2,253
Source: Bloomberg	

#### **Shareholding Structure**

Golden Link Worldwide Ltd	65.76%
Gold Dragonfly Ltd	6.08%
Vanguard Group Inc	1.20%
Source: Bloomberg	

#### **Share Performance**

	Absolute	Relative
1-mth	-2.1%	-0.7%
3-mth	6.3%	1.0%
6-mth	8.7%	-10.7%
Source: Bloomberg	3	

--- -- -- J

### 12-mth Price Performance



Source: Bloomberg

## **Auditor: Ernst & Young**

### Related reports:

- 1. Partnership with Xiaomi to fuel new wave of growth 6 Nov 2020
- Positive profit alert and strong outlook; Reiterate BUY – 14 Oct 2020
- 3. Multiple growth drivers ahead; Lift TP to HK\$37.7 31 Aug 2020



# **Earnings Revision**

Figure 1: FY20 results review

					СМВІ		Conse	nsus
RMB mn	FY18	FY19	FY20	YoY	FY20E	Diff%	FY20E	Diff%
Revenue	41,047	53,028	73,121	38%	76,422	-4%	78,694	-7%
Gross profit	4,172	3,957	9,629	143%	9,702	-1%	10,071	-4%
Operating profit	1,818	994	5,806	484%	5,577	4%	5,943	-2%
Net profit	2,146	1,598	5,441	241%	5,489	-1%	5,513	-1%
EPS (RMB)	0.95	0.71	2.41	241%	2.44	-1%	2.45	-1%
Gross margin	10.2%	7.5%	13.2%	5.7ppt	12.7%	0.5 ppt	12.8%	0.4 ppt
Operating margin	4.4%	1.9%	7.9%	6.1ppt	7.3%	0.6 ppt	7.6%	0.4 ppt
Net margin	5.2%	3.0%	7.4%	4.4ppt	7.2%	0.3 ppt	7.0%	0.4 ppt

Source: Company data, Bloomberg, CMBIS estimates

Figure 2: Quarterly results review

		•	•	·		СМЕ	SI .
RMB mn	4Q19	1Q20	2Q20	3Q20	4Q20	4Q20E	Diff%
Revenue	14,630	8,564	22,822	20,131	21,604	24,904	-13%
Gross profit	1345	1064	3035	3386	2143	2,216	-3%
Net profit	571	657	1815	1862	1107	1,154	-4%
EPS (RMB)	0.25	0.29	0.81	0.82	0.49	0.52	-4%
Growth (YoY)							
Revenue	27%	-18%	77%	33%	48%	70%	
Gross profit	47%	27%	325%	219%	59%	65%	
Net profit	66%	69%	869%	312%	94%	102%	
<u>Margin</u>							
Gross margin	9.2%	12.4%	13.3%	16.8%	9.9%	9%	1 ppt
Net margin	3.9%	7.7%	8.0%	9.2%	5.1%	5%	0.5 ppt

Source: Company data, Bloomberg, CMBIS estimates

Figure 3: Earnings revision

DMD mm	New			Old			Change (%)		
RMB mn	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E
Revenue	102,033	122,932	151,077	102,923	130,941	na	-1%	-6%	na
Gross Profit	10,700	12,279	14,788	10,983	12,847	na	-3%	-4%	na
Operating Profit	5,905	6,501	7,687	6,043	6,562	na	-2%	-1%	na
Net profit	5,878	6,404	7,448	6,148	6,627	na	-4%	-3%	na
EPS (RMB)	2.61	2.84	3.31	2.73	2.94	na	-4%	-3%	na
Gross Margin	10.5%	10.0%	9.8%	10.7%	9.8%	na	-0.2 ppt	0.2 ppt	na
Operating Margin	5.8%	5.3%	5.1%	5.9%	5.0%	na	-0.1 ppt	0.3 ppt	na
Net Margin	5.8%	5.2%	4.9%	6.0%	5.1%	na	-0.2 ppt	0.1 ppt	na

Sources: Company data, CMBIS estimates

Figure 4: CMBIS estimates vs consensus

DMD		CMBIS			Consensus		Diff (%)			
RMB mn	FY21E	FY22E	FY23E	FY21E	FY22E	FY22E	FY21E	FY22E	FY23E	
Revenue	102,033	122,932	151,077	101,688	119,964	132,551	0%	2%	14%	
Gross Profit	10,700	12,279	14,788	11,027	12,717	14,846	-3%	-3%	0%	
Operating Profit	5,905	6,501	7,687	4,893	5,246	7,175	21%	24%	7%	
Net profit	5,878	6,404	7,448	4,922	5,527	7,019	19%	16%	6%	
EPS (RMB)	2.61	2.84	3.31	2.21	2.51	3.30	18%	13%	0%	
Gross Margin	10.5%	10.0%	9.8%	10.8%	10.6%	11.2%	-0.4 ppt	-0.6 ppt	-1.4 ppt	
Operating Margin	5.8%	5.3%	5.1%	4.8%	4.4%	5.4%	1 ppt	0.9 ppt	-0.3 ppt	
Net Margin	5.8%	5.2%	4.9%	4.8%	4.6%	5.3%	0.9 ppt	0.6 ppt	-0.4 ppt	

Source: Company data, CMBIS estimates



Figure 5: Revenue breakdown

RMB mn	1H19	2H19	FY19	1H20	2H20	FY20	FY21E	FY22E	FY23E
Assembly	11,865	14,982	26,847	9,909	21,243	31,152	60,000	74,000	92,000
YoY	38%	68%	53%	-16%	42%	16%	93%	23%	24%
Phone and PC component	8,056	10,506	18,562	8,615	8,961	17,576	20,452	23,587	27,484
YoY	-8%	13%	3%	7%	-15%	-5%	16%	15%	17%
Metal	7,995	5,469	13,000	5,528	5,476	10,996		8,785	9,526
Plastic	3,881	1,725	3,512	2,841	1,415	4,566		3,687	3,687
Glass/ceramic	5,700	863	1,500	2,138	1,725	3,000		7,980	10,374
Mask	-	-	-	8,548	3,552	12,100	3,388	1,694	847
YoY							-72%	-50%	-50%
New intelligent products	-	-	-	-	-	1,000	2,000	2,600	3,380
YoY							100%	30%	30%
Auto intelligent systems	2,598	3,427	6,025	3,634	5,842	9,476	13,740	17,862	23,221
YoY	55%	29%	39%	40%	70%	57%	45%	30%	30%
Total	761	833	1,594	680	1,137	1,817	2,453	3,189	4,145
YoY	55%	19%	34%	-11%	36%	14%	35%	30%	30%

Source: Company data, CMBIS estimates

Figure 6: P&L forecast by interim

RMB mn	1H19	2H19	FY19	1H20	2H20	FY20	FY21E	FY22E	FY23E
Revenue	23,280	29,748	53,028	31,386	41,735	73,121	102,033	122,932	151,077
YoY	19.3%	38.1%	29.2%	34.8%	40.3%	37.9%	39.5%	20.5%	22.9%
Cost of sales	(21,729)	(27,342)	(49,071)	(27,286)	(36,206)	(63,492)	(91,332)	(110,654)	(136,290)
Gross profit	1,551	2,406	3,957	4,100	5,529	9,629	10,700	12,279	14,788
GPM (%)	7%	8%	7%	13%	13%	13%	10%	10%	10%
YoY	-34.6%	-20.3%	-5.1%	96.0%	63.8%	143.3%	11.1%	14.7%	20.4%
SG&A	(428)	(448)	(876)	(405)	(505)	(910)	(918)	(1,106)	(1,360)
% of rev	2%	2%	2%	1%	1%	1%	1%	1%	1%
R&D	(853)	(1,235)	(2,088)	(1,108)	(1,806)	(2,913)	(3,877)	(4,671)	(5,741)
% of rev	4%	4%	4%	4%	4%	4%	4%	4%	4%
Operating profit	270	723	994	2,587	3,218	5,806	5,905	6,501	7,687
OPM (%)	1%	2%	2%	8%	8%	8%	6%	5%	5%
YoY	-78%	-35%	-45%	610%	217%	484%	2%	10%	18%
Net profit	575	1,022	1,598	2,473	2,969	5,441	5,878	6,404	7,448
NPM (%)	2%	3%	3%	8%	7%	7%	6%	5%	5%
YoY	-49%	1%	-26%	330%	190%	241%	8%	9%	16%

Source: Company data, CMBIS estimates



## **Valuation**

## Reiterate BUY with new TP HK\$ 56.2 (33% upside)

We maintain Buy with new TP HK\$ 56.2, as we turn more positive on share gain with Xiaomi/Apple and stronger e-cigarette sales. We derive our TP of HK\$ 56.2 based on SOTP valuation to reflect BYDE's business diversification with different growth profiles and visibility.

Our new TP is based on weighted-average target P/E multiple of 17.9x FY21E EPS. We assign 15x P/E to its assembly EMS business and 20x P/E for component business, in-line with TW/HK-listed peers. We assign lower 8x for mask business to reflect its near-term growth potential amid COVID-19 outbreak.

Figure 7: BYDE - SOTP valuation

Business segment	% of FY21E Profit	FY21E EPS (RMB)	Target P/E
Assembly	16%	0.42	15x
Components	37%	0.95	20x
Masks	11%	0.29	8x
Others (smart, auto)	36%	0.95	20x
Total (RMB) /Implied P/E		2.61	16.3x
TP (HK\$)			56.2

Sources: Company data, CMBIS estimates

Figure 8: Peers' valuation

igui e ei i			Market			Up/						
			Сар	Price	TP	Down	P/E	(x)	P/E	3 (x)	ROE	(%)
Company	Ticker	Rating	(US\$ mn)	(LC)	(LC)	-side	FY20E	FY21E	FY20E	FY21E	FY20E	FY21E
BYDE	285 HK	Buy	12,273	42.35	56.2	33%	14.6	13.5	5.3	4.2	24.9	21.6
Tongda	698 HK	Buy	458	0.55	0.56	2%	11.2	6.9	0.5	0.5	4.7	7.7
AAC Tech	2018 HK	Hold	6,140	39.50	45.3	15%	28.3	23.5	2.0	1.9	6.9	8.0
TK Group	2283 HK	Buy	316	2.95	4.1	39%	5.3	4.6	1.9	1.9	35.7	41.7
Ju Teng	3336 HK	NR	332	2.15	NA	NA	6.5	6.5	0.4	0.4	6.4	6.1
Everwin	300115 CH	NR	3,248	21.33	NA	NA	34.3	21.0	3.9	3.4	12.1	17.4
Lens Tech	300433 CH	NR	19,450	25.70	NA	NA	25.0	19.2	4.0	3.3	18.0	19.0
Foxconn	2354 TT	NR	3,710	74.80	NA	NA	15.4	14.3	0.8	0.8	6.3	6.3
Catcher	2474 TT	NR	5,661	212.00	NA	NA	10.0	12.5	1.0	1.0	16.5	7.4
			Average				16.9	13.7	2.2	1.8	14.0	13.9


Source: Bloomberg, CMBIS estimates, \*TP under review

Figure 9: 12M forward P/E band

25 20 15 10 5 Mar-14 Mar-15 Mar-16 Mar-17 Mar-19 Mar-20 Mar-21 1-yr Forward P/E Mean - - - Mean+1SD Mean-1SD

Source: Bloomberg, CMBIS estimates

Figure 10: 12M forward P/B band



Source: Bloomberg, CMBIS estimates



# **Financial Summary**

Income statement						Cash flow summary					
YE 31 Dec (RMB mn)	FY19E					YE 31 Dec (RMB mn)	FY19E	FY20A	FY21E	FY22E	FY23E
Revenue	53,028		102,033				1,696	6,221	6,680	7,278	8,464
COGS	(49,071)	(63,492)	(91,332)	(110,65	(136,29	Depreciation	2,157	2,442	2,839	3,318	3,907
Gross profit	3,957	9,629	10,700	12,279	14,788	Change in working capital	(3,596)	(1,499)	(1,982)	1,075	(5,914)
						Others	(20)	(708)	(730)	(802)	(944)
Selling and marketing	(257)	(237)	(306)	(369)	(453)	Net cash from operating	237	6,455	6,806	10,869	5,512
Administrative	(619)	(673)	(612)	(738)	(906)						
R&D	(2,088)	(2,913)	(3,877)	(4,671)	(5,741)	Capex	(3,140)	(2,632)	(3,673)	(4,426)	(5,439)
Other operating exp.						Other					
Operating profit	994	5,806	5,905	6,501	7,687	Net cash from investing	(3,140)	(2,632)	(3,673)	(4,426)	(5,439)
Financial cost	(31)	(71)	(71)	(71)	(71)	Dividend paid	(160)	(543)	(588)	(640)	(745)
Other income/(losses)	734	487	846	848	848	Other	(31)	(71)	(71)	(71)	(71)
Pre-tax profit	1,696	6,221	6,680	7,278		Net cash from financing	(191)	(614)	(659)	(712)	(816)
Tax	(99)	(779)	(802)	(873)	(1,016)	Net change in cash	(3,095)	3,209	2,474	5,732	(743)
Minority interest	-	-	-	-	-	Cash at beginning of the year	4,699	1,651	4,859	7,333	13,065
Net profit	1,598	5,441	5,878	6,404		0 0 ,					
·						Cash at the end of the year	1,651	4,859	7,333	13,065	12,322

Balance sheet						Key ratios					
YE 31 Dec (RMB mn)	FY19E	FY20A	FY21E	FY22E	FY23E	YE 31 Dec	FY19E	FY20A	FY21E	FY22E	FY23E
Current assets	17,082	25,250	34,200	39,883	51,352	Sales mix (%)					
Cash & equivalents	1,651	4,859	7,333	13,065	12,322	Phone and PC components	35	24	20	19	18
Account receivables	9,567	11,324	15,884	14,849	22,921	Assembly services	51	43	59	60	61
Inventories	5,453	8,656	10,572	11,559	15,699	Masks					
Short-term bank deposits	-	-	-	-	-	New intelligent products	11	13	13	15	15
Other current assets	411	411	411	411	411	Auto intelligent systems	3	2	2	3	3
						Growth (%)					
Non-current assets	9,950	10,123	10,882	11,888	13,281	Revenue	29.2	37.9	39.5	20.5	22.9
PPE	8,617	8,808	9,642	10,750	12,282	Gross profit	(5.1)	143.3	11.1	14.7	20.4
Deferred income tax	159	159	159	159	159	Operating profit	(45.4)	484.3	1.7	10.1	18.2
Other non-current assets	1,173	1,156	1,080	980	840	Net profit	(25.5)	240.6	8.0	9.0	16.3
Total assets	27,032	35,374	45,082	51,772	64,633						
						Profit & loss ratio (%)					
Current liabilities	10,399	13,860	18,353	19,380	25,678	Gross margin	7.5	13.2	10.5	10.0	9.8
Deferred income						Operating margin	1.9	7.9	5.8	5.3	5.1
Account payables	7,340	10,801	15,294	16,321	22,619	Net profit margin	3.0	7.4	5.8	5.2	4.9
Tax payable	108	108	108	108	108						
Other current liabilities	2,951	2,951	2,951	2,951	2,951	Balance sheet ratio					
						Net debt/total equity (x)	Net	Net	Net	Net	Net
Non-current liabilities	639	639	639	639	639	Current ratio (x)	1.6	1.8	1.9	2.1	2.0
Deferred income	122	122	122	122	122	Receivable turnover days	58	52	49	46	46
Deferred tax liability	18	18	18	18	18	Inventory turnover days	38	41	38	37	37
Total liabilities	11,038	14,498	18,992	20,019	26,316	Payable turnover days	57	52	52	52	52
Share capital	4,052	4,052	4,052	4,052	4,052	Profitability (%)					
Reserves	12,937	17,836	23,126	28,890	35,593		9.4	24.9	21.6	19.4	18.8
Minority interest	•	•	•	•	•	ROA	5.9	15.4	13.0	12.4	11.5
Shareholders' equity	16,989	21,888	27,178	32,942	39,645						
Total equity and liabilities	28,027	36,386	46,170	52,961	65,962	Per share data (RMB)					
	•	•	•	•	•	EPS	0.71	2.41	2.61	2.84	3.31
						DPS	0.07	0.24	0.26	0.28	0.33

Source: Company data, CMBIS estimates



# **Disclosures & Disclaimers**

## **Analyst Certification**

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

### **CMBIS** Ratings

BUY
Stock with potential return of over 15% over next 12 months

HOLD
SELL
Stock with potential return of +15% to -10% over next 12 months

SELL
Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIS

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

### CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

### **Important Disclosures**

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS and/or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS. Additional information on recommended securities is available upon request.

## For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc...) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

## For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.